Synlogic’s SYNB1891 strain was engineered to target the stimulator of interferon genes (STING) agonists pathway to trigger anti-tumour immunity, via expression of cyclic di-AMP (CDA) (Leventhal et al., 2020). Here, STING1 is linked to neoplasm.